InvestorsHub Logo
Followers 13
Posts 552
Boards Moderated 0
Alias Born 12/23/2020

Re: stockorus post# 173443

Wednesday, 07/07/2021 9:39:35 PM

Wednesday, July 07, 2021 9:39:35 PM

Post# of 233272
Quote:
In other words, the RTF Letter resulted from the FDA’s conclusions that the Company’s disclosures and presentations in the BLA were deficient, which was the unforeseen result of certain of the Company’s prior regulatory consultants not performing work consistent with professional standards and their representations, including a third party laboratory’s receptor occupancy analysis.

Interesting reading. Is this the RO from Incelldx?
 

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News